EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness

Antonio Gil-Nagel, Kelly G Knupp iD, Boudewijn Gunning, Domenica Immacolata Battaglia, Elizabeth A Thiele iD, Ingrid E Scheffer, An-Sofie Schoonjans iD, Rima Nabbout, Nathalie Villeneuve, Kerstin Alexandra Klotz iD, Nicola Specchio, Rocio Sanchez-Carpintero iD und 7 weitere

Epilepsia · 2026

DOI: 10.1002/epi.70371 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Epilepsia, 2026. Verfasst von Antonio Gil-Nagel und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Ruber Internacional, Madrid, Spain. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Myoclonic, Fenfluramine, Lennox Gastaut Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB, University of California Berkeley.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Long‐term safety and global functioning are reported in patients with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS) treated with fenfluramine in an open‐label extension (OLE) study after participating in a previous open‐label feeder study.

Methods

Patients could enroll in this international, multicenter OLE (NCT03936777) after completing one of three fenfluramine open‐label studies. The latest feeder study fenfluramine dose was continued, then flexibly titrated (maximum: .7 mg/kg/day [26 mg/day] without stiripentol or .4 mg/kg/day [17 mg/day] with stiripentol), with ≥1 concomitant antiseizure medication administered. Primary endpoint was fenfluramine long‐term safety/tolerability. Global functioning using caregiver‐ and investigator‐reported Clinical Global Impression of Improvement (CGI–I) ratings, globally and for subdomains (cognition, behavior, motor function), at last visit relative to study baseline was evaluated. Overall treatment exposure and age groups were analyzed post hoc.

Results

A total of 412 patients enrolled (DS: 265 [64.3%], LGS: 147 [35.7%]); 30.8% were ≥18 years old. Median fenfluramine treatment duration in this OLE was 729.5 days (range = 8–1544), and overall median fenfluramine exposure, including feeder studies, was 1464.5 days (range = 171–2800). In this OLE, ≥1 treatment‐emergent adverse event (TEAE) was reported in 311 (75.5%) patients; fenfluramine‐related (per investigator) serious TEAEs were reported in five (1.2%) patients. Three patients died in this OLE (deemed unrelated to fenfluramine by investigators). After starting this OLE already receiving fenfluramine, 373 of 401 (93.0%) and 376 of 401 (93.8%) patients were rated by caregiver and investigator, respectively, as “improved or no change” on CGI–I versus this study baseline; subdomain ratings of “improved or no change” were largely consistent with global assessment. Significance In our OLE study of patients with DS or LGS treated with fenfluramine (up to 4 years), no new or unexpected safety signals were observed; global functioning was improved or stable (vs. study baseline) in >90% of patients, supporting long‐term fenfluramine use in pediatric and adult patients with DS or LGS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsies, MyoclonicFenfluramineLennox Gastaut SyndromeAdolescentAdultChildChild, PreschoolFemaleHumansMaleYoung AdultTreatment Outcome

Stichwörter der Autor:innen

CGI–IDSLGSdevelopmental and epileptic encephalopathyseizure

Substanzen

AnticonvulsantsFenfluramine

Autor:innen und Institutionen

  • Hospital Ruber Internacional, Madrid, Spain.
  • University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.
  • Stichting Epilepsie Instellingen Nederland, Zwolle, the Netherlands.
  • Fondazione Policlinico Universitario Agostino Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
  • Università Cattolica del Sacro Cuore, Rome, Italy.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Kelly G Knupp, Elizabeth A Thiele, An-Sofie Schoonjans, Kerstin Alexandra Klotz, Rocio Sanchez-Carpintero, Amélie Lothe

Förderung

  • UCB
  • University of California Berkeley

Zitieren

APA

Gil-Nagel, A., Knupp, K. G., Gunning, B., Battaglia, D. I., Thiele, E. A., Scheffer, I. E., Schoonjans, A. S., Nabbout, R., Villeneuve, N., Klotz, K. A., Specchio, N., Sanchez-Carpintero, R., Zolnowska, M., Schulz, A. L., Perrin, L., Dickson, N., Langlois, M., Lothe, A., & Sullivan, J. (2026). Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness. Epilepsia. https://doi.org/10.1002/epi.70371

Vancouver

Gil-Nagel A, Knupp KG, Gunning B, Battaglia DI, Thiele EA, Scheffer IE, et al. Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness. Epilepsia. 2026. doi:10.1002/epi.70371

BibTeX
@article{GilNagel2026,
  author = {Gil-Nagel, Antonio and Knupp, Kelly G and Gunning, Boudewijn and Battaglia, Domenica Immacolata and Thiele, Elizabeth A and Scheffer, Ingrid E and Schoonjans, An-Sofie and Nabbout, Rima and Villeneuve, Nathalie and Klotz, Kerstin Alexandra and Specchio, Nicola and Sanchez-Carpintero, Rocio and Zolnowska, Marta and Schulz, Anne-Liv and Perrin, Lily and Dickson, Najla and Langlois, Mélanie and Lothe, Amélie and Sullivan, Joseph},
  title = {Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1002/epi.70371}
}
Kostenlos starten →